Changes in healthcare utilization and costs associated with sildenafil therapy for pulmonary arterial hypertension: a retrospective cohort study
نویسندگان
چکیده
BACKGROUND Little is known concerning the degree to which initiation of sildenafil for pulmonary arterial hypertension (PAH) impacts patterns of healthcare utilization and costs. METHODS Using a large US health insurance claims database, we identified all patients with evidence of PAH (ICD-9-CM diagnosis codes 416.0, 416.8) who received sildenafil between 1/1/2005 and 9/30/2008. Date of the first-noted prescription for sildenafil was designated the "index date," and claims data were compiled for all study subjects for 6 months prior to their index date ("pretreatment") and 6 months thereafter ("follow-up"); patients with incomplete data during either of these periods were excluded. Healthcare utilization and costs were then compared between pretreatment and follow-up for all study subjects. RESULTS A total of 567 PAH patients were identified who began therapy with sildenafil and met all other study entry criteria. Mean (SD) age was 52 (10) years; 73% were women. Healthcare utilization was largely unchanged between pretreatment and follow-up, the only exceptions being decreases in the mean number of emergency department visits (from 0.7 to 0.5 per patient; p<0.01) and the percentage of patients hospitalized (from 35% to 29%; p=0.01). The mean cost of all PAH-related medication was $7139 during pretreatment and $14,095 during follow-up (sildenafil cost during follow-up= $5236); exclusive of PAH-related medications, however, total healthcare costs decreased modestly (from $30,104 to $27,605) (p<0.01 for all comparisons). CONCLUSIONS The cost of sildenafil therapy may be partially offset by reductions in other healthcare costs.
منابع مشابه
A case of severe pulmonary hypertension associated with common arterial trunk and VSD in a 9 years old child
Background: Common arterial trunk (CAT) is a rare congenital heart disease, and often leads to the early development of pulmonary hypertension and disability. Among the critical structural heart defects, the frequency of CAT is 3%, which reflects the severe hemodynamic disturbances. The natural course of the disease is characterized by a high mortality rate up to 88% during the first year of li...
متن کاملتعیین شاخص های فارماکوکینتیکی شربت سیلدنافیل در هیپرتانسیون ریوی کودکان
Background and purpose: Pulmonary arterial hypertension (PAH) is a fatal disease affecting patients in all ages that could result in acute and chronic heart failure with high mortality rate. Oral sildenafil is approved to treat PAH in adults and recently in children. There are limited studies on the pharmacokinetics parameters of sildenafil, therefore, this study was designed to determine the p...
متن کاملSurvival with sildenafil and inhaled iloprost in a cohort with pulmonary hypertension: an observational study.
BACKGROUND Combination therapy is frequently used to treat patients with pulmonary hypertension but few studies have compared treatment regimens. This study examined the long-term effect of different combination regimens of inhaled iloprost and oral sildenafil on survival and disease progression. METHODS This was a retrospective study of patients in the Giessen Pulmonary Hypertension Registry...
متن کاملThe Characteristics of Treated Pulmonary Arterial Hypertension Patients in Ontario
Background. There are no Canadian prevalence studies on pulmonary arterial hypertension (PAH) to date. We described the characteristics of treated PAH patients and the healthcare utilization and costs associated with PAH in a population of public drug plan beneficiaries in Ontario, Canada. Methods. A retrospective cross-sectional analysis was conducted between April 2010 and March 2011 to ident...
متن کاملبررسی اثر تادالافیل خوراکی در کاهش پرفشاری شریان ریوی در کودکان و نوجوانان 5 ماهه تا 15 ساله
Introduction: Pulmonary arterial hypertension in children has consequences such as right ventricular failure and even death. Recently, the use of phosphodiesterase 5 inhibitors has been taken into account in the treatment of pulmonary hypertension, among which tadalafil is more acceptable by parents and patients due to its single dose per day compared to sildenafil which should be taken 4 times...
متن کامل